New cancer advances from the birthplace of precision medicine
From sequencing the first complete genome of a cancer patient to developing genomic tests for guiding optimal cancer treatment, WashU Medicine has been at the forefront of individualized patient care.
Matt MillerLulu Sun, MD, PhD, and Shelly O’Laughlin, director of clinical operations, discuss the DNA sequencers and GatewaySEQ on February 9, 2024. Medicare approved WashU Medicine’s genetic test for solid tumors, which can quickly identify treatable cancer mutations and guide precision therapy. MATT MILLER/WASHINGTON UNIVERSITY SCHOOL OF MEDICINE